SecBot SecBot
PRESS-RELEASE ·Filed Apr 30, 2026

COAG

Hemab Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonimmediate Processed6mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight • Neutral

Monitor first-day trading volume and price action for signs of demand. The $301.5M raise provides a multi-year cash runway for pipeline development, but as a clinical-stage company with no approved products, near-term catalysts depend on clinical trial data readouts for sutacimig and HMB-002.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$34.00
T+0 close · Apr 30, 2026 · via day close
Latest settled
+39.00%
T+60 · $47.26
Vs SPY
+35.93%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 1 $34.00entry
  2. T+1 · 7mo ago −25.47%α −25.13% · $25.34
  3. T+5 · 6mo ago −26.12%α −28.46% · $25.12
  4. T+20 · 6mo ago −20.21%α −25.47% · $27.13
  5. T+60 · 4mo ago +39.00%α +35.93% · $47.26

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Hemab Therapeutics priced its IPO at $18.00 per share, offering 16.75M shares for gross proceeds of ~$301.5M, with an underwriter option for an additional 2.5125M shares. The stock begins trading on Nasdaq May 1, 2026 under ticker COAG. This is a dilutive event for existing holders but provides capital to advance its clinical pipeline in blood coagulation disorders.

Key Financial Metrics

Deal Value
$301.5M

Key Facts

  • IPO priced at $18.00 per share for 16,750,000 shares
  • Gross proceeds of approximately $301.5 million before expenses
  • Underwriters have a 30-day option to purchase up to 2,512,500 additional shares
  • Trading begins on Nasdaq Global Select Market on May 1, 2026 under ticker COAG
  • Goldman Sachs, Jefferies, and Evercore ISI are joint book-running managers
  • Offering expected to close on or about May 4, 2026
  • Company is a clinical-stage biotech focused on blood coagulation disorders

Financial Impact

Gross proceeds of ~$301.5M from IPO, representing significant capital infusion for a clinical-stage biotech

dilutioncash

Risk Factors

  • Dilution for existing shareholders from the 16.75M share offering
  • Clinical-stage company with no approved products or revenue
  • Potential for underwriters to exercise overallotment option, adding further dilution
  • Market conditions may affect post-IPO trading performance

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3285621

Track record

19 reports on COAG

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $38.77 Now $39.06 +0.75% settles Nov 17
  2. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $42.81 to $39.06 Now $39.06 −8.76% ▼ −8.77% −7.08% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $49.02 to $40.86 Now $39.06 −20.32% ▼ −16.65% −19.24% vs SPY
  4. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $45.09 to $39.33 Now $39.06 −13.37% ▼ −12.77% −11.86% vs SPY
  5. Sep 25, 20267w ago 3 Neutral 2/10 Entry $33.12 to $30.59 Now $39.06 +17.93% ▼ −7.64% −8.84% vs SPY
  6. Sep 17, 20268w ago Press Release Neutral 4/10 Entry $41.22 to $35.72 Now $39.06 −5.24% ▼ −13.34% −14.19% vs SPY
  7. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $49.87 to $52.44 Now $39.06 −21.68% ▲ +5.15% +5.56% vs SPY
  8. Jun 17, 202621w ago Insider Buy Neutral 2/10 Entry $29.24 to $27.72 Now $39.06 +33.58% ▼ −5.20% −3.53% vs SPY
  9. May 21, 202625w ago Press Release Neutral 5/10 Entry $26.30 to $28.50 Now $39.06 +48.52% ▲ +8.37% +6.52% vs SPY
  10. May 4, 202628w ago 8-K Neutral 4/10 Entry $25.00 to $25.90 Now $39.06 +56.24% ▲ +3.60% +1.62% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens Wed (10h 12m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 30, 2026